Shares of ViroPharma (VPHM) sink 18.4% premarket after rivals Watson Pharmaceuticals and Akorn...

|By:, SA News Editor

Shares of ViroPharma (VPHM) sink 18.4% premarket after rivals Watson Pharmaceuticals and Akorn (AKRX) both launch generic versions of Vancocin. The company says that it intends to file a complaint seeking an injunction to set aside the FDA approvals on the drugs and restore its exclusivity.